Kenvue (NYSE:KVUE) Given Sector Perform Rating at Royal Bank of Canada

Royal Bank of Canada reissued their sector perform rating on shares of Kenvue (NYSE:KVUE) in a research report report published on Monday,Benzinga reports. They currently have a $24.00 price target on the stock.

A number of other equities research analysts have also commented on the stock. Citigroup decreased their price objective on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. UBS Group lowered their price target on shares of Kenvue from $24.00 to $23.00 and set a “neutral” rating for the company in a report on Thursday, January 16th. Barclays reduced their price objective on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a report on Friday, January 17th. Bank of America lifted their target price on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. Finally, JPMorgan Chase & Co. upped their price target on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $23.08.

Kenvue Stock Down 0.4 %

NYSE KVUE opened at $20.74 on Monday. The stock’s 50 day simple moving average is $21.77 and its 200 day simple moving average is $21.96. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue has a one year low of $17.67 and a one year high of $24.46. The firm has a market cap of $39.76 billion, a PE ratio of 37.70, a price-to-earnings-growth ratio of 2.05 and a beta of 1.45.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company had revenue of $3.90 billion for the quarter, compared to analysts’ expectations of $3.92 billion. During the same quarter in the prior year, the business earned $0.31 earnings per share. The business’s revenue for the quarter was down .4% on a year-over-year basis. As a group, sell-side analysts forecast that Kenvue will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be paid a $0.205 dividend. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.95%. Kenvue’s dividend payout ratio (DPR) is presently 149.09%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Grove Bank & Trust raised its holdings in Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after purchasing an additional 947 shares during the period. Riverview Trust Co bought a new stake in shares of Kenvue in the 3rd quarter valued at $30,000. Geneos Wealth Management Inc. acquired a new stake in Kenvue during the 4th quarter worth $29,000. SRS Capital Advisors Inc. raised its stake in Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock worth $30,000 after buying an additional 571 shares during the period. Finally, Ashton Thomas Securities LLC acquired a new position in Kenvue in the third quarter valued at about $35,000. Institutional investors own 97.64% of the company’s stock.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.